Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of halcinonide and derivative thereof in preparation of medicine for treating and/or preventing cerebrovascular diseases

A technology for cerebrovascular diseases and derivatives, applied in the field of medicine, can solve the problems of cerebrovascular diseases without the application of hacinide

Active Publication Date: 2021-07-06
上海普佑生物医药有限公司
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is currently no literature on the application of halcinonide to cerebrovascular diseases, nor any literature suggesting that halcinonide has the function of treating cerebrovascular diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of halcinonide and derivative thereof in preparation of medicine for treating and/or preventing cerebrovascular diseases
  • Application of halcinonide and derivative thereof in preparation of medicine for treating and/or preventing cerebrovascular diseases
  • Application of halcinonide and derivative thereof in preparation of medicine for treating and/or preventing cerebrovascular diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0069] Example 1. Study on the Effect of Halcinonide in Treating Ischemic Stroke

[0070] 1. Experimental animals

[0071] 3-month-old SPF male SD rats were selected, with a body weight of 200±20 g. Provided by Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences. No drugs were used before the experiment. The experimental animals were fed for one week in an environment with a temperature of 24-26°C and a 12h / 12h regular alternation of daylight hours, and the animals were given food and water freely, and then the experiments were performed in groups.

[0072] 2. Drugs and reagents

[0073] Halcinonide, purchased from Shanghai Macklin Biochemical Technology Co., Ltd., batch number: C11650940, molecular weight formula C 24 h 32 ClFO 5 , with a molecular weight of 454.96

[0074]Butylphthalide soft capsules (Butylphthalide, NBP), purchased from CSPC NBP Pharmaceutical Co., Ltd.;

[0075] 2,3,5-Triphenyltetrazolium chloride (TTC) was purchased fro...

Embodiment 2

[0101] Example 2. Study on the Effect of Prednisone in Treating Ischemic Stroke

[0102] 1. The specific implementation method is the same as embodiment one.

[0103] Prednisone (Prednisone) was purchased from Shanghai Macklin Biochemical Technology Co., Ltd., batch number: C11008416, and the molecular formula is C 21 h 26 o 5 , the molecular weight is 358.43. For the experimental grouping, see Example 1. The halcinonide group was replaced by the prednisone group. The administration method was gavage, and the dose was 20 mg / kg / d. Model preparation and detection indicators are the same as in Example 1.

[0104] 2. Experimental results

[0105] (1) Assessment of neurological deficit score

[0106] SD rats were administered for 1 day, and after 2 hours of ischemia in the MCAO model, they were treated with drugs again, and after 24 hours of reperfusion, the neurofunctional and behavioral scores of rats in each group were shown in the appendix. Figure 4 . Such as Figure ...

Embodiment 3

[0109] Example 3. Study on the Effect of Testosterone Propionate in Treating Ischemic Stroke

[0110] 1. Refer to Embodiment 1 for the specific implementation method.

[0111] Testosterone Propionate (Testosterone Propionate) was purchased from Shanghai Aladdin Biochemical Technology Co., Ltd., batch number: A1910098, and the molecular formula is C 22 h 32 o 3 , the molecular weight is 344.49. For the experimental grouping, see Example 1. The halcinonide group was replaced by the testosterone propionate group. The administration method was gavage, and the dose was 20 mg / kg / d. Model preparation and detection indicators are the same as in Example 1.

[0112] 2. Experimental results

[0113] (1) Assessment of neurological deficit score

[0114] SD rats were administered for 1 day, and after 2 hours of ischemia in the MCAO model, they were treated with drugs again, and after 24 hours of reperfusion, the neurofunctional and behavioral scores of rats in each group were shown i...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of medicines, in particular to application of halcinonide and a derivative thereof in preparation of a medicine for treating and / or preventing cerebrovascular diseases. The halcinonide and the derivative thereof have a structural general formula shown in formula (I), and the treatment effect of the halcinonide and the derivative thereof on ischemic cerebral stroke is evaluated through an MCAO cerebral ischemia-reperfusion injury animal model. Experimental results show that the halcinonide and the derivatives thereof prednisone and testosterone propionate can significantly improve the score of animal neurological impairment and reduce the area of infarct focus, can be used for treating ischemic stroke, and have good clinical application prospects.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the application of halcinonide and derivatives thereof in the preparation of medicines for treating and / or preventing cerebrovascular diseases. Background technique [0002] Stroke (Stroke) is a common clinical disease with high morbidity. It has the characteristics of high morbidity, high mortality and high disability rate. It is the first cause of death in my country and the second leading cause of death in the world. It seriously affects the quality of life of patients, and hemiplegia often occurs after treatment, which brings huge economic and social burdens. With the increase of the aging population in my country, the incidence of stroke is gradually increasing. Stroke is divided into ischemic stroke and hemorrhagic stroke, of which ischemic stroke accounts for 60% to 70% of the total stroke. A general term for brain tissue necrosis caused by stenosis or occlusion, insuff...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/58A61K31/573A61K31/567A61K31/565A61K31/566A61P9/10
CPCA61K31/58A61K31/573A61K31/567A61K31/565A61K31/566A61P9/10
Inventor 陈新平赵文阳刘菁菁李响响
Owner 上海普佑生物医药有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com